9PT.F PLIANT THERA.INC.DL-0001

Healthcare Biotechnology Frankfurt Exchange
0.6990 EUR
Close of Nov 11, 2026
0.6945 1.42
Market cap
EUR 43.3M
P/E
-
P/B
0.34x
ROE
-57.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 9PT.F undervalued?

Graham number

The Graham number of PLIANT THERA.INC.DL-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PLIANT THERA.INC.DL-0001 fundamental analysis

No fundamental analysis for PLIANT THERA.INC.DL-0001 yet.

PLIANT THERA.INC.DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PLIANT THERA.INC.DL-0001

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusin…

Full company profile